Anil Vachani

faculty photo
Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center
Attending Physician, Philadelphia Veterans Administration Medical Center
Director of Clinical Research, Section of Interventional Pulmonology and Thoracic Oncology, Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania School of Medicine
Director of Bronchoscopy, Philadelphia VA Medical Center
Director, Lung Nodule Program, Perelman School of Medicine, Univeristy of Pennsylvania
Associate Director, Masters in Translational Research Program, ITMAT Educational Programs
Co-Director Lung Cancer Screening Program, Perelman School of Medicine, University of Pennslvania
Department: Medicine

Contact information
Pulmonary, Allergy, and Critical Care Division
University of Pennsylvania School of Medicine
Suite 216, Stemmler Hall
3450 Hamilton Walk
Philadelphia, PA 19104
Office: 215.573.7931
Education:
B.S. (Genetics)
University of California, Berkeley, 1992.
B.A. (Economics)
University of California, Berkeley, 1992.
M.D. (Medicine)
University of California, San Francisco, 1996.
M.S. (Clinical Epidemiology)
University of Pennsylvania, Perelman School of Medicine, 2013.
Permanent link
 

Description of Itmat Expertise

Dr. Vachani is interested in the molecular epidemiology of lung cancer and in discovery and validation of early detection biomarkers for thoracic malignancies. His research ranges from animal models to human translational studies and includes observational and correlative studies in early and late phase clinical trials.

Selected Publications

Bagley SJ, Talento S, Mitra N, Meropol NJ, Cohen RB, Langer CJ, Vachani A: Comparative Effectiveness of Carboplatin-Pemetrexed With vs Without Bevacizumab in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network (in press), Nov 2018.

Weng L, Guo L, Vachani A, Mesaros C, Blair IA.: Quantification of Serum High Mobility Group Box 1 by Liquid Chromatography/High-Resolution Mass Spectrometry: Implications for Its Role in Immunity, Inflammation, and Cancer. Anal Chem 90(12): 7552-7560, Jun 2018.

Silvestri GA, Tanner NT, Kearney P, Vachani A, Massion PP, Porter A, Springmeyer SC, Fang KC, Midthun D, Mazzone PJ; PANOPTIC Trial Team: Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial. Chest March 2018.

Morris S, Vachani A, Pass HI, Rom WN, Ryden K, Weiss GJ, Hogarth DK, Runger G, Richards D, Shelton T, Mallery DW: Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer. Int J Cancer Jan 2018.

Huang J., Liu Y., Vitale S., Penning T.M., Whitehead A.S., Blair I.A., Vachani A., Clapper M., Muscat J.E., Lazarus P., Scheet P., Moore J.H., Chen Y.: On meta- and mega-analyses for gene–environment interactions. Genetic Epidemiology November 2017.

Aggarwal C, Wang X, Ranganathan A, Torigian D, Troxel A, Evans T, Cohen RB, Vaidya B, Rao C, Connelly M, Vachani A, Langer C, Albelda S: Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy. Lung Cancer 112: 118-125, Oct 2017.

Tanner NT, Porter A, Gould MK, Li XJ, Vachani A, Silvestri GA: Physician Assessment of Pretest Probability of Malignancy and Adherence With Guidelines for Pulmonary Nodule Evaluation. Chest 152(2): 263-270, Aug 2017.

Xu R, Mesaros C, Weng L, Snyder NW, Vachani A, Blair IA, Hwang WT: Comparison of statistical methods for detection of serum lipid biomarkers for mesothelioma and asbestos exposure. Biomarkers in Medicine 11(7): 547-556, Jul 2017.

Schonewolf CA, Verma V, Post CM, Berman AT, Frick MA, Vachani A, Lin C, Simone CB: Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Lung Cancer (Amsterdam, Netherlands) Jul 2017.

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ: Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 106: 1-7, Apr 2017.

back to top
Last updated: 12/16/2018
The Trustees of the University of Pennsylvania